Unveiling the Roles of HBV Polymerase for New Antiviral Strategies

Overview

Journal Future Virol

Specialty Microbiology

Date 2015 Apr 21

PMID 25893003

Citations 26

Authors

Daniel N Clark

Jianming Hu

Affiliations

Soon will be listed here.

Abstract

Infection with HBV is common worldwide, with over 350 million chronic carriers. Chronic HBV infection is associated with cirrhosis and hepatocellular carcinoma. All currently available oral antivirals are directed against the HBV polymerase enzyme, a reverse transcriptase. HBV polymerase contains several important domains and motifs which define its functions and reveal ways to further target it. This enzyme executes many functions required for the HBV replication cycle, including viral RNA binding, RNA packaging, protein priming, template switching, DNA synthesis and RNA degradation. In addition, HBV polymerase must interact with host proteins for its functions. Future therapeutics may inhibit not only the DNA synthesis steps which are carried out by the reverse transcriptase domain (as all current antivirals do) but other domains, functions and interactions which are essential to the HBV replication cycle.

Citing Articles

Viral infection, APOBEC3 dysregulation, and cancer.

Lehle J, Soleimanpour M, Mokhtari S, Ebrahimi D Front Genet. 2025; 15:1489324.

PMID: 39764440 PMC: 11701051. DOI: 10.3389/fgene.2024.1489324.

Generation of Replication-Competent Hepatitis B Virus Harboring Tagged Polymerase for Visualization and Quantification of the Infection.

Morita C, Wada M, Ohsaki E, Kimura-Ohba S, Ueda K Microbiol Immunol. 2024; 69(1):43-58.

PMID: 39620377 PMC: 11701411. DOI: 10.1111/1348-0421.13183.

Regulation of Hepatitis B Virus Replication by Modulating Endoplasmic Reticulum Stress (ER-Stress).

Hossain M, Ueda K Int J Microbiol. 2024; 2024:9117453.

PMID: 39246409 PMC: 11379510. DOI: 10.1155/2024/9117453.

Deep mutational scanning of hepatitis B virus reveals a mechanism for cis-preferential reverse transcription.

Yu Y, Kass M, Zhang M, Youssef N, Freije C, Brock K Cell. 2024; 187(11):2735-2745.e12.

PMID: 38723628 PMC: 11127778. DOI: 10.1016/j.cell.2024.04.008.

Full-Length Genome Sequencing and Analysis of Hepatitis B Viruses Isolated from Iraqi Patients.

Mamoori Y, Ahmed I, Mahmood A, Al-Waysi S Int J Microbiol. 2024; 2024:6826495.

PMID: 38716461 PMC: 11074772. DOI: 10.1155/2024/6826495.

References

Tantillo C, Ding J, Nanni R, Boyer P, Hughes S, Pauwels R . Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol. 1994; 243(3):369-87. DOI: 10.1006/jmbi.1994.1665. View

Corsa A, Liu Y, Flaherty J, Mitchell B, Fung S, Gane E . No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol. 2014; 12(12):2106-12.e1. DOI: 10.1016/j.cgh.2014.05.024. View

Ding J, Nanni R, Clark Jr A, Lu X, Tantillo C, Williams R . Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993; 90(13):6320-4. PMC: 46920. DOI: 10.1073/pnas.90.13.6320. View

Wang Y, Wen Y, Nassal M . Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids. J Virol. 2012; 86(18):10079-92. PMC: 3446557. DOI: 10.1128/JVI.00816-12. View

Shin Y, Ko C, Ryu W . Hydrophobic residues of terminal protein domain of hepatitis B virus polymerase contribute to distinct steps in viral genome replication. FEBS Lett. 2011; 585(24):3964-8. DOI: 10.1016/j.febslet.2011.11.003. View

Karatayli E, Karayalcin S, Karaaslan H, Kayhan H, Turkyilmaz A, Sahin F . A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther. 2007; 12(5):761-8. View

Menendez-Arias L, Alvarez M, Pacheco B . Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol. 2014; 8:1-9. DOI: 10.1016/j.coviro.2014.04.005. View

Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T . DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. J Virol. 2007; 81(24):13922-6. PMC: 2168844. DOI: 10.1128/JVI.01517-07. View

Seeger C, Mason W . Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000; 64(1):51-68. PMC: 98986. DOI: 10.1128/MMBR.64.1.51-68.2000. View

10.

Das K, Xiong X, Yang H, Westland C, Gibbs C, Sarafianos S . Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol. 2001; 75(10):4771-9. PMC: 114232. DOI: 10.1128/JVI.75.10.4771-4779.2001. View

11.

Ghany M, Liang T . Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology. 2007; 132(4):1574-85. DOI: 10.1053/j.gastro.2007.02.039. View

12.

Gu L, Fullam A, Brennan R, Schroder M . Human DEAD box helicase 3 couples IκB kinase ε to interferon regulatory factor 3 activation. Mol Cell Biol. 2013; 33(10):2004-15. PMC: 3647972. DOI: 10.1128/MCB.01603-12. View

13.

Tan Y, Ge G, Zhao W, Gan J, Zhao Y, Niu Z . YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis. 2012; 16(3):250-5. View

14.

Seeger C, Leber E, Wiens L, Hu J . Mutagenesis of a hepatitis B virus reverse transcriptase yields temperature-sensitive virus. Virology. 1996; 222(2):430-9. DOI: 10.1006/viro.1996.0440. View

15.

Huang H, Chopra R, Verdine G, Harrison S . Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science. 1998; 282(5394):1669-75. DOI: 10.1126/science.282.5394.1669. View

16.

Langley D, Walsh A, Baldick C, Eggers B, Rose R, Levine S . Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007; 81(8):3992-4001. PMC: 1866160. DOI: 10.1128/JVI.02395-06. View

17.

Glebe D, Urban S, Knoop E, Cag N, Krass P, Grun S . Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology. 2005; 129(1):234-45. DOI: 10.1053/j.gastro.2005.03.090. View

18.

Nowotny M, Gaidamakov S, Crouch R, Yang W . Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell. 2005; 121(7):1005-16. DOI: 10.1016/j.cell.2005.04.024. View

19.

Mukaide M, Tanaka Y, Shin-I T, Yuen M, Kurbanov F, Yokosuka O . Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. Antimicrob Agents Chemother. 2009; 54(2):882-9. PMC: 2812155. DOI: 10.1128/AAC.01061-09. View

20.

Gong Y, Yao E, Stevens M, Tavis J . Evidence that the first strand-transfer reaction of duck hepatitis B virus reverse transcription requires the polymerase and that strand transfer is not needed for the switch of the polymerase to the elongation mode of DNA synthesis. J Gen Virol. 2000; 81(Pt 8):2059-2065. DOI: 10.1099/0022-1317-81-8-2059. View